ERBB2 and neoplasm: Importantly, combinations of these small molecules with anti-HER2 mAbs not only resulted in stronger tumor growth inhibition than monotherapy with individual small molecules or mAbs but also exhibited better antitumor effects than the current standard of care (trastuzumab combined with pertuzumab).